48 completed, 3 withdrawn, 2 terminated. 28 Phase 2, 18 Phase 3, 15 Phase 1, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 28 | Completed 24, Withdrawn 3, Terminated 1 |
| Phase 3 | 18 | Completed 16, Withdrawn 2 |
| Phase 1 | 15 | Completed 14, Withdrawn 1 |
| Phase 4 | 3 | Completed 2, Terminated 1 |
Follow Novavax: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of NVX-CoV2705 NVX-CoV2705, Placebo - COVID-19, Sars-CoV-2 Infection | Phase 4 | Terminated | Novavax | 6500 | 2025-11-20 | 2026-10-23 |
| Safety and Immunogenicity of NVX-CoV2705 NVX-CoV2705 - COVID-19, SARS-CoV-2 Infection | Phase 3 | Completed | Sanofi | 676 | 2025-10-09 | 2026-06-05 |
| Lot Consistency Study of COVID-19 and Influenza Combination Vaccine coformulated CIC Vaccine, Fluzone HD trivalent - COVID-19, Influenza | Phase 2 / Phase 3 | Withdrawn | Novavax | 2025-02-01 | 2025-03-11 | |
| A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, Novavax COVID-19 Vaccine, tNIV Vaccine - COVID-19 | Phase 3 | Completed | Novavax | 9320 | 2024-12-09 | 2026-06-05 |
| Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine tNIV 1 and Matrix-M Adjuvant - COVID-19 | Phase 2 / Phase 3 | Withdrawn | Novavax | 2024-11-01 | 2025-03-11 | |
| A Strain Change Study for SARS-CoV-2 rS Vaccines NVX-CoV2705 Vaccine - Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Phase 3 | Completed | Novavax | 60 | 2024-10-14 | 2025-07-18 |
| Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine - COVID-19, Vaccine-Preventable Diseases | Phase 4 | Completed | Novavax | 660 | 2024-09-19 | 2026-06-02 |
| The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing) - COVID-19, Vaccine-Preventable Diseases | Phase 4 | Completed | Sarang K. Yoon, DO, MOH | 1188 | 2023-11-22 | 2026-01-28 |
| Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations NVX-CoV2372 - Immunosuppression, COVID-19 | Phase 2 | Completed | University of Wisconsin, Madison | 21 | 2023-11-20 | 2025-10-20 |
| Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), NVX-CoV2601(5μg) - COVID-19 | Phase 2 / Phase 3 | Completed | Novavax | 994 | 2023-10-16 | 2024-12-13 |
| A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose) - COVID-19 | Phase 2 / Phase 3 | Completed | Novavax | 660 | 2023-09-07 | 2024-05-30 |
| Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg) - COVID-19 | Phase 3 | Completed | Novavax | 400 | 2023-08-16 | 2025-07-15 |
| Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant - COVID-19 | Phase 3 | Completed | Novavax | 147 | 2023-03-28 | 2025-06-26 |
| A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine qNIV Vaccine with Matrix-M Adjuvant, Influenza Vaccine, CIC Vaccine with Matrix-M Adjuvant - COVID-19, Influenza | Phase 2 | Completed | Novavax | 1579 | 2022-12-30 | 2024-07-16 |
| Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo - COVID-19 | Phase 2 / Phase 3 | Completed | Novavax | 3600 | 2022-07-22 | 2026-05-22 |
| Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults NVX-Cov2373 - COVID-19, SARS-CoV-2 Infection | Phase 3 | Completed | Novavax | 911 | 2022-07-11 | 2026-04-17 |
| Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines NVX-CoV2515, NVX-Cov2373, NVX-CoV2373 + NVX-CoV2515 - COVID-19, SARS CoV 2 Infection | Phase 3 | Completed | Novavax | 1340 | 2022-05-25 | 2024-04-23 |
| Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine NVX-CoV2373, BBIBP-CorV vaccine - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Phase 3 | Completed | Cogna Technology Solutions LLC | 1000 | 2022-03-18 | 2023-08-02 |
| A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19) NVX-CoV2373 - SARS-CoV-2 Infection | Phase 2 | Completed | Novavax | 384 | 2022-02-28 | 2023-03-16 |
| Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults SII B.1.351, SII Bivalent, SII B.1.617.2 - Covid19 | Phase 1 / Phase 2 | Withdrawn | Novavax | 2022-02-04 | 2022-05-31 |
Showing 20 of 53. Sign in to see all of them.
COVID-19 (24) · Influenza, Human (14) · Coronavirus Infections (7) · Respiratory Syncytial Virus Infections (4) · Malaria (2) · Malaria, Falciparum (2) · Severe Acute Respiratory Syndrome (2) · Vaccine-Preventable Diseases (2) · Hemorrhagic Fever, Ebola (1) · Influenza in Birds (1) · Respiration Disorders (1) · Respiratory Tract Infections (1)
NVX-CoV2373 adjuvated lipid nanoparticle (14) · Adjuvants, Pharmaceutic (6) · Sodium Chloride (5) · Influenza Vaccines (4) · Matrix-M (4) · Injections (3) · Immunization, Secondary (2) · BIBP COVID-19 vaccine (1) · Fluzone High-Dose (1) · Hepatitis A Vaccines (1) · YY1 Transcription Factor (1)
United States (34) · Australia (11) · Mexico (4) · South Africa (4) · New Zealand (3) · United Kingdom (3) · Philippines (2) · Spain (2) · Argentina (1) · Bangladesh (1) · Canada (1) · Chile (1) · Colombia (1) · Dominican Republic (1) · Guatemala (1)
D. Nigel Thomas, Ph.D. (6) · Nigel Thomas, Ph.D (2) · Nigel Thomas, Ph.D. (2) · Constantino R Lopez Macias, M.D. (1) · D Nigel Thomas, Ph.D. (1) · D. Nigel Thomas, Ph. D. (1) · David L Freid, M.D. (1) · Dennis Ruff, MD (1) · Freddy Caldera, DO, MS (1) · George Atiee, M.D. (1) · Issaka Sagara, MD (1) · John E Ervin, M.D. (1) · Larry Gilderman, D.O. (1) · Laurence Chu, M.D. (1)
PMID 23153449, PMID 24224560, PMID 26259809, PMID 28413427, PMID 28579233, PMID 31402384, PMID 32726529, PMID 32877576, PMID 33139139, PMID 33146720, PMID 33446655, PMID 33951374, PMID 34563277, PMID 34597298, PMID 34800364, PMID 34910859, PMID 35489376, PMID 35963274, PMID 36172135, PMID 37099299, PMID 37127523, PMID 37210741, PMID 37271706, PMID 37385888, PMID 37652823, PMID 38365482, PMID 38460525, PMID 38649867, PMID 39052718, PMID 39225478, PMID 39787798, PMID 39824198, PMID 39884302, PMID 40184816, PMID 40632654, PMID 41117170, PMID 41455184, PMID 41592795, PMID 42811742